Table 8 Adverse events in ≥ 3 patients by talabostat dose level.
From: Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
----Talabostat Dose BID--- | |||
|---|---|---|---|
System Organ Classa | 300 mcg | 400 mcg | Overall |
Preferred term | (n = 74)b | (n = 44) | (N = 74) |
Blood and Lymphatic System Disorders | 32 (43.2) c | 19 (43.2) | 41 (55.4) |
Anaemiad | 20 (27.0) | 11 (25.0) | 29 (39.2) |
Thrombocytopeniae | 13 (17.6) | 8 (18.2) | 18 (24.3) |
Neutropeniaf | 12 (16.2) | 5 (11.4) | 14 (18.9) |
Leukopeniag | 4 (5.4) | 4 (9.1) | 7 (9.5) |
Cardiac Disorders | 2 (2.7) | 3 (6.8) | 5 (6.8) |
Palpitations | 2 (2.7) | 1 (2.3) | 3 (4.1) |
Ear and Labyrinth Disorders | 15 (20.3) | 5 (11.4) | 19 (25.7) |
Tinnitus | 10 (13.5) | 4 (9.1) | 13 (17.6) |
Hypoacusis | 4 (5.4) | 1 (2.3) | 5 (6.8) |
Eye Disorders | 9 (12.2) | 7 (15.9) | 13 (17.6) |
Vision blurred | 2 (2.7) | 4 (9.1) | 6 (8.1) |
Gastrointestinal Disorders | 54 (73.0) | 21 (47.7) | 58 (78.4) |
Nausea | 38 (51.4) | 11 (25.0) | 44 (59.5) |
Vomiting NOS | 31 (41.9) | 10 (22.7) | 38 (51.4) |
Constipation | 22 (29.7) | 7 (15.9) | 25 (33.8) |
Diarrhoea NOS | 9 (12.2) | 5 (11.4) | 13 (17.6) |
Abdominal pain NOS | 3 (4.1) | 4 (9.1) | 7 (9.5) |
Dyspepsia | 2 (2.7) | 3 (6.8) | 5 (6.8) |
Stomatitis | 1 (1.4) | 2 (4.5) | 3 (4.1) |